Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-17 DOI:10.1007/s11897-024-00686-6
Leah B Kosyakovsky, Rudolf A de Boer, Jennifer E Ho
{"title":"Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.","authors":"Leah B Kosyakovsky, Rudolf A de Boer, Jennifer E Ho","doi":"10.1007/s11897-024-00686-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Heart failure (HF) represents a growing global burden of morbidity and mortality. Identifying individuals at risk for HF development is increasingly important, particularly given the advent of disease-modifying therapies for HF as well as its major risk factors such as obesity actalnd diabetes. We aim to review the key circulating biomarkers associated with future HF which may contribute to HF risk prediction.</p><p><strong>Recent findings: </strong>While current guidelines recommend the use of natriuretic peptides and cardiac troponins in HF risk stratification, there are a diverse array of other emerging protein, metabolic, transcriptomic, and genomic biomarkers of future HF development. These biomarkers not only lend insight into the underlying pathophysiology of HF, which spans inflammation to cardiac fibrosis, but also offer an opportunity to further refine HF risk in addition to established biomarkers. As evolving techniques in molecular biology enable an increased understanding of the complex biologic contributions to HF pathophysiology, there is an important opportunity to construct integrated clinical and multi-omic models to best capture HF risk. Moving forward, future studies should seek to understand the contributions of sex differences, underlying comorbidity burden, and HF subtypes to an individual's HF risk. Further studies are necessary to fully define the clinical utility of biomarker screening approaches to refine HF risk assessment, as well as to link risk assessment directly to preventive strategies for HF.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"591-603"},"PeriodicalIF":3.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-024-00686-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Heart failure (HF) represents a growing global burden of morbidity and mortality. Identifying individuals at risk for HF development is increasingly important, particularly given the advent of disease-modifying therapies for HF as well as its major risk factors such as obesity actalnd diabetes. We aim to review the key circulating biomarkers associated with future HF which may contribute to HF risk prediction.

Recent findings: While current guidelines recommend the use of natriuretic peptides and cardiac troponins in HF risk stratification, there are a diverse array of other emerging protein, metabolic, transcriptomic, and genomic biomarkers of future HF development. These biomarkers not only lend insight into the underlying pathophysiology of HF, which spans inflammation to cardiac fibrosis, but also offer an opportunity to further refine HF risk in addition to established biomarkers. As evolving techniques in molecular biology enable an increased understanding of the complex biologic contributions to HF pathophysiology, there is an important opportunity to construct integrated clinical and multi-omic models to best capture HF risk. Moving forward, future studies should seek to understand the contributions of sex differences, underlying comorbidity burden, and HF subtypes to an individual's HF risk. Further studies are necessary to fully define the clinical utility of biomarker screening approaches to refine HF risk assessment, as well as to link risk assessment directly to preventive strategies for HF.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心力衰竭筛查:检测普通人群高风险的生物标志物。
回顾的目的:心力衰竭(HF)是一个日益严重的全球性发病和死亡负担。鉴别心力衰竭高危人群的重要性与日俱增,特别是考虑到心力衰竭疾病修饰疗法的出现以及肥胖和糖尿病等主要风险因素。我们旨在回顾与未来心房颤动有关的主要循环生物标志物,这些标志物可能有助于心房颤动风险预测:尽管目前的指南建议在高血压风险分层中使用钠尿肽和心肌肌钙蛋白,但未来高血压发展的蛋白质、代谢、转录组和基因组生物标志物也多种多样。这些生物标志物不仅能帮助人们深入了解从炎症到心脏纤维化的心房颤动潜在病理生理学,还能在已有的生物标志物之外提供进一步完善心房颤动风险的机会。随着分子生物学技术的不断发展,人们对心房颤动病理生理学的复杂生物作用有了更多的了解,这为构建综合临床和多组学模型以最佳捕捉心房颤动风险提供了重要机会。展望未来,未来的研究应寻求了解性别差异、潜在合并症负担和高频亚型对个人高频风险的贡献。有必要开展进一步的研究,以充分确定生物标志物筛查方法在完善心房颤动风险评估方面的临床效用,并将风险评估与心房颤动的预防策略直接联系起来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Heart Failure Reports
Current Heart Failure Reports Medicine-Emergency Medicine
CiteScore
5.30
自引率
0.00%
发文量
44
期刊介绍: This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
期刊最新文献
Cardiogenic Shock: Focus on Non-Cardiac Biomarkers. Biomarkers of Hemodynamic Congestion in Heart Failure. Heart Failure in Rheumatoid Arthritis: Clinical Implications. Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1